Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Castle Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DELIVERED Q3 2025 REVENUE OF $83 MILLION Q 3 2025 NON-DERMATOLOGIC REVENUE INCREASED BY 67% OVER Q 3 2024 Q 3 2025 TOTAL TEST REPORTS FOR OUR CORE REVENUE DRIVERS (DECISIONDX  -MELANOMA, TISSUECYPHER  ) INCREASED 36% OVER Q 3 2024 RAISING FULL-YEAR 2025 REVENUE GUIDANCE TO $327-335 MILLION FROM $ 310-320 MILLION ANNOUNCED LAUNCH OF ADVANCEAD-TX, THE COMPANY'S TEST DESIGNED TO GUIDE SYSTEMIC TREATMENT DECISION MAKING IN PATIENTS AGES 12 AND OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD) CONFERENCE CALL AND WEBCAST TODAY AT 4:30 P.M. ET FRIENDSWOOD, TEXAS, NOV. 03, 2025 (GLOBE NEWSWIRE) -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPT.

CASTLE BIOSCIENCES REPORTS THIRD QUARTER 2025 RESULTS

FRIENDSWOOD, TEXAS, NOV. 03, 2025 (GLOBE NEWSWIRE) -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THE LAUNCH OF ADVANCEAD-TX, A GENE EXPRESSION PROFILE (GEP) TEST DESIGNED TO GUIDE SYSTEMIC TREATMENT DECISION MAKING IN PATIENTS AGES 12 AND OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD). THIS INNOVATIVE 487-GEP TEST IS DESIGNED TO IDENTIFY PATIENTS WITH A JANUS KINASE INHIBITOR (JAKI) RESPONDER PROFILE WHO ARE MORE LIKELY TO ACHIEVE AN ECZEMA AREA AND SEVERITY INDEX IMPROVEMENT OF 90% (EASI-90), MORE QUICKLY AND WITH REDUCTION OF FLARES AND ITCH BY THREE MONTHS WHEN TREATED WITH A JAK INHIBITOR THAN THOSE TREATED WITH A T HELPER TYPE 2 (TH2)-TARGETED THERAPY.

CASTLE BIOSCIENCES LAUNCHES ADVANCEAD-TX TO HELP GUIDE SYSTEMIC TREATMENT DECISION MAKING IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

FRIENDSWOOD, TEXAS, OCT. 28, 2025 (GLOBE NEWSWIRE) -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT ITS EXECUTIVE MANAGEMENT IS SCHEDULED TO PRESENT A COMPANY OVERVIEW AT THE STEPHENS 27TH ANNUAL INVESTMENT CONFERENCE ON WEDNESDAY, NOV. 19, 2025, AT 10:00 A.M. EASTERN TIME.

CASTLE BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

FRIENDSWOOD, TEXAS, OCT. 26, 2025 (GLOBE NEWSWIRE) -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED NEW DATA DEMONSTRATING THAT ITS TISSUECYPHER BARRETT'S ESOPHAGUS TEST CAN PROVIDE RISK INSIGHTS BEYOND PATHOLOGY ALONE, INFLUENCING CLINICAL MANAGEMENT TO SUPPORT EARLIER INTERVENTION FOR THOSE AT HIGHER RISK OF PROGRESSION TO ESOPHAGEAL CANCER AND POTENTIALLY REDUCING UNNECESSARY PROCEDURES FOR THOSE AT LOWER RISK. THE RESEARCH WILL BE PRESENTED IN THREE POSTERS AT THE AMERICAN COLLEGE OF GASTROENTEROLOGY (ACG) 2025 ANNUAL SCIENTIFIC MEETING, TAKING PLACE OCT. 2729, 2025, IN PHOENIX, ARIZONA, INCLUDING ONE SELECTED FOR A PRESIDENTIAL POSTER AWARD.

NEW DATA AT AMERICAN COLLEGE OF GASTROENTEROLOGY ANNUAL MEETING SHOW TISSUECYPHER PROVIDES ACTIONABLE RISK INSIGHTS THAT INFLUENCE CLINICAL MANAGEMENT AND PROMPT RISK-ALIGNED INTERVENTION IN BARRETT'S ESOPHAGUS

CASTLE IS PRESENTING DATA ON DECISIONDX-MELANOMA AND ITS PIPELINE ATOPIC DERMATITIS (AD) TEST AT THE 25TH ANNUAL FALL CLINICAL DERMATOLOGY CONFERENCE.

NEW ANALYSIS OF 13,560 PATIENTS DEMONSTRATES DECISIONDX-MELANOMA STRATIFIES RISK ACROSS HISTOLOGICAL SUBTYPES; FINDINGS TO BE PRESENTED AT FALL CLINICAL DERMATOLOGY CONFERENCE

FRIENDSWOOD, TEXAS, OCT. 13, 2025 (GLOBE NEWSWIRE) -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPT. 30, 2025, AFTER THE CLOSE OF MARKET ON MONDAY, NOV. 3, 2025.

CASTLE BIOSCIENCES TO RELEASE THIRD QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON MONDAY, NOV. 3, 2025

FRIENDSWOOD, TEXAS, OCT. 01, 2025 (GLOBE NEWSWIRE) -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT ITS FOUNDER, PRESIDENT AND CHIEF EXECUTIVE OFFICER DEREK MAETZOLD HAS BEEN AWARDED THE CEO OF THE YEAR BY THE CEO MAGAZINE. THE EXECUTIVE OF THE YEAR AWARDS PROGRAM RECOGNIZES SENIOR EXECUTIVES DRIVING MEASURABLE IMPACT, INNOVATION AND INSPIRATION.

CASTLE BIOSCIENCES' FOUNDER, PRESIDENT AND CEO DEREK MAETZOLD HONORED WITH THE CEO OF THE YEAR AWARD BY THE CEO MAGAZINE

FRIENDSWOOD, TEXAS, SEPT. 23, 2025 (GLOBE NEWSWIRE) -- CASTLE BIOSCIENCES, INC.(NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT IT HAS BEEN RECOGNIZED AS A GREATER PITTSBURGH TOP WORKPLACE BY THE PITTSBURGH POST-GAZETTE.

CASTLE BIOSCIENCES HONORED WITH A GREATER PITTSBURGH TOP WORKPLACES 2025 AWARD

FRIENDSWOOD, TEXAS, SEPT. 17, 2025 (GLOBE NEWSWIRE) -- CASTLE BIOSCIENCES, INC.(NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, HAS BEEN INCLUDED IN THE INAUGURAL 2025 AMERICA'S GREATEST COMPANIES LIST, PUBLISHED BY NEWSWEEK.

CASTLE BIOSCIENCES NAMED ONE OF NEWSWEEK'S AMERICA'S GREATEST COMPANIES 2025

FRIENDSWOOD, TEXAS, SEPT. 09, 2025 (GLOBE NEWSWIRE) -- CASTLE BIOSCIENCES, INC.(NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT NEW DATA DEMONSTRATING THE PERSONALIZED RISK STRATIFICATION PROVIDED BY ITS TISSUECYPHER BARRETT'S ESOPHAGUS TEST WILL BE SHARED VIA A PODIUM PRESENTATION AT THE AMERICAN FOREGUT SOCIETY'S (AFS) 2025 ANNUAL MEETING, TAKING PLACE SEPT.

NEW DATA AT AMERICAN FOREGUT SOCIETY'S 2025 ANNUAL MEETING DEMONSTRATES TISSUECYPHER CAN DETECT HIGH-RISK BARRETT'S ESOPHAGUS PATIENTS NOT IDENTIFIED BY PATHOLOGY TO SUPPORT IMPROVED CARE DECISIONS

NEW VALIDATION STUDY SHOWS DECISIONDX-SCC SIGNIFICANTLY OUTPERFORMS CURRENT STAGING SYSTEMS IN PREDICTING RISK OF LOCAL RECURRENCE AND METASTASIS FOR NCCN HIGH-RISK PATIENTS CLINICIAN SURVEY CONFIRMS TEST RESULTS ALIGN WITH TREATMENT DECISION-MAKING THRESHOLDS FOR ADJUVANT RADIATION THERAPY AND SURVEILLANCE IMAGING FRIENDSWOOD, TEXAS, AUG. 25, 2025 (GLOBE NEWSWIRE) -- CASTLE BIOSCIENCES, INC. (NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THE PUBLICATION OF TWO NEW STUDIES RELATED TO ITS DECISIONDX-SCC TEST, ADDING TO ITS VALIDATED USES FOR PATIENTS WITH HIGH-RISK CUTANEOUS SQUAMOUS CELL CARCINOMA (SCC).1,2 DECISIONDX-SCC IS A GENE EXPRESSION PROFILE TEST (40-GEP) DESIGNED TO USE A PATIENT'S TUMOR BIOLOGY TO PREDICT INDIVIDUAL RISK OF METASTASIS AS WELL AS RESPONSE TO ADJUVANT RADIATION THERAPY (ART). THE FIRST STUDY REPRESENTS AN EXPANDED CLINICAL USE MILESTONE, DEMONSTRATING THAT DECISIONDX-SCC PREDICTS LOCAL RECURRENCE IN PATIENTS CLASSIFIED AS HIGH-RISK BY NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES WHO HAVE UNDERGONE MOHS RESECTION, THEREBY ADDING A THIRD USE TO THE TEST'S EXISTING CAPABILITIES.

NEW EVIDENCE PUBLISHED SUPPORTING USE OF DECISIONDX-SCC TEST IN GUIDING AND IMPROVING TREATMENT PATHWAY DECISIONS IN NCCN HIGH-RISK CUTANEOUS SQUAMOUS CELL CARCINOMA

FRIENDSWOOD, TEXAS, AUG. 21, 2025 (GLOBE NEWSWIRE) -- CASTLE BIOSCIENCES, INC.(NASDAQ: CSTL), A COMPANY IMPROVING HEALTH THROUGH INNOVATIVE TESTS THAT GUIDE PATIENT CARE, TODAY ANNOUNCED THAT ITS EXECUTIVE MANAGEMENT IS SCHEDULED TO PRESENT A COMPANY OVERVIEW AT BAIRD'S 2025 GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, SEPT. 10, 2025, AT 10:15 A.M.

Castle Biosciences, Inc.

CSTL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Castle Biosciences, Inc.

CSTL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CSTL